Radiolabeled Liposome Delivery to Bypass the Blood-Brain Barrier
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glioblastoma and leptomeningeal metastases, such as external beam radiation therapy, are limited by their inability to target tumors near critical brain structures without harming surrounding normal tissues, and existing radiotherapeutics struggle to penetrate the blood-brain barrier, leading to ineffective survival outcomes and significant side effects.
Innovation Solution
The use of radiolabeled liposomes, specifically those containing 99mTc, 186Re, or 188Re, are administered via convection-enhanced delivery to directly target and treat glioblastoma and leptomeningeal metastases, allowing precise localization and minimizing damage to normal brain tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If external beam radiation therapy is used to treat glioblastoma and leptomeningeal metastases, then tumor coverage is achieved, but surrounding normal brain tissues are harmed
Solution Approach 1:
The patent applies local quality by using liposomes with surface-modified regions that selectively interact with tumor cells while leaving surrounding normal tissues unaffected. The liposome surface is functionalized with specific ligands or antibodies that bind to tumor markers, creating a localized therapeutic effect only at the tumor site.
Solution Approach 2:
The liposome serves as an intermediary carrier that delivers radiation or chemotherapeutic agents directly to tumor cells. The liposome membrane acts as a protective barrier that prevents direct exposure of normal tissues to harmful treatments while allowing controlled release of therapeutic agents at the tumor site.
2Reliability
If systemic chemotherapy is administered to treat leptomeningeal metastases, then tumor cells are targeted, but the blood-brain barrier prevents effective delivery
Solution Approach 1:
The liposome acts as an intermediary that circumvents the blood-brain barrier through convection-enhanced delivery. The liposomes are injected into the cerebrospinal fluid or brain tissue, allowing direct penetration into the central nervous system without requiring systemic circulation to cross the blood-brain barrier.
Solution Approach 2:
The patent utilizes convection-enhanced delivery, which employs fluid dynamics principles to transport liposomes through the cerebrospinal fluid and into tumor sites. The delivery system uses pressure gradients and fluid flow to facilitate direct injection and distribution of therapeutic liposomes within the central nervous system.
3Reliability
If conventional radiation therapy is used, then tumor sites are irradiated, but treatment duration is extended and quality of life is reduced
Solution Approach 1:
The liposome-based therapy provides continuous localized action by maintaining therapeutic agents at the tumor site over an extended period. The liposomes can be designed to release their payload slowly and continuously, providing sustained treatment effect without requiring prolonged external beam radiation sessions.
Solution Approach 2:
The liposomes are designed to autonomously target and deliver therapy to tumor cells through their surface modifications and convection-enhanced delivery mechanisms. Once administered, the liposomes self-navigate to tumor sites and provide sustained therapeutic action without requiring continuous external intervention or prolonged treatment protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances treatment efficacy by prolonging survival and maintaining quality of life by delivering therapeutic doses directly to the tumor sites while reducing side effects, as demonstrated by improved survival rates and tumor response.
Implementation Method 1
administered via convection-enhanced delivery to directly target and treat glioblastoma and leptomeningeal metastases
Implementation Method 2
existing radiotherapeutics struggle to penetrate the blood-brain barrier
Data Source
AI summary
Radiolabeled liposomes can be used in the treatment of cancer. These local therapies can be used to treat cancers including, but not limited to, leptomeningeal metastases. In an embodiment, radiolabeled liposomes comprising (186Re) obisbemeda can be administered to a patient through an Ommaya reservoir. The therapies can include imaging the radiolabeled liposome concomitant or subsequent to administration.